[18F]fluoroethyltyrosine-positron emission tomography-based therapy monitoring after stereotactic iodine-125 brachytherapy in patients with recurrent high-grade glioma

Molecular Imaging

Volumn 12, Issue 3, 2013, Pages

  Jansen, Nathalie L ^a   Suchorska, Bogdana ^a   Schwarz, Silke B ^a   Eigenbrod, Sabina ^a   Lutz, Juergen ^a   Graute, Vera ^a   Bartenstein, Peter ^a   Belka, Claus ^a   Kreth, Friedrich W ^a   La Fougère, Christian ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH-GRADE GLIOMATA; LOCAL TUMOR PROGRESSIONS; MISCLASSIFICATIONS; MULTI VARIATE ANALYSIS; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARD MODELS; THERAPEUTIC EFFECTS; THERAPEUTIC INTERVENTION;

DIAGNOSIS; IODINE; MAGNETIC RESONANCE IMAGING; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOTHERAPY;

TUMORS;

IODINE; O-(2-FLUOROETHYL)TYROSINE; TYROSINE;

ANALOGS AND DERIVATIVES; BRACHYTHERAPY; DISEASE FREE SURVIVAL; GLIOMA; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES;

BRACHYTHERAPY; DISEASE-FREE SURVIVAL; GLIOMA; HUMANS; IODINE; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; TYROSINE;

EID: 84879195501     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2012.00027     Document Type: Article

References (38)

1. Stupp R, Roila F. Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20 Suppl 4:126-8.
2. Bernstein M, Gutin PH. Interstitial irradiation of brain tumors: a review. Neurosurgery 1981;9:741-50, doi:10.1227/00006123-198112000-00022.
3. Julow J, Kolumban Z, Viola A, et al. Prediction of volumetric change in the ''triple ring'' caused by glioma I-125 brachytherapy. Neuro Oncol 2008;10:583-92, doi:10.1215/15228517-2008-027.
4. Kumar AJ, Leeds NE, Fuller GN, et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapyinduced necrosis of the brain after treatment. Radiology 2000; 217:377-84.
5. Giglio P, Gilbert MR. Cerebral radiation necrosis. Neurologist 2003;9:180-8, doi:10.1097/01.nrl.0000080951.78533.c4.
6. Fike JR, Cann CE, Davis RL, et al. Radiation effects in the canine brain evaluated by quantitative computed tomography. Radiology 1982;144:603-8.
7. Piroth MD, Pinkawa M, Holy R, et al. Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2011;80:176-84, doi:10.1016/j.ijrobp.2010.01.055.
8. Voges J, Herholz K, Holzer T, et al. 11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds. Stereotact Funct Neurosurg 1997;69:129-35, doi:10.1159/000099864.
9. Mehrkens JH, Popperl G, Rachinger W, et al. The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. J Neurooncol 2008;88:27-35, doi:10.1007/s11060-008-9526-4.
10. Popperl G, Goldbrunner R, Gildehaus FJ, et al. O-(2-[18F]fluoroethyl)-L- tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging 2005;32: 1018-25, doi:10.1007/s00259-005-1819-7.
11. Popperl G, Gotz C, Rachinger W, et al. Value of O-(2- [18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 2004;31:1464-70, doi:10.1007/s00259-004-1590-1.
12. Popperl G, Gotz C, Rachinger W, et al. Serial O-(2-[(18)F]fluoroethyl)-L- tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging 2006;33:792-800, doi:10.1007/s00259-005-0053-7.
13. Rachinger W, Goetz C, Popperl G, et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 2005;57:505-11; discussion 511, doi:10.1227/01.NEU.0000171642.49553.B0.
14. Ostertag CB, Kreth FW. Iodine-125 interstitial irradiation for cerebral gliomas. Acta Neurochir (Wien) 1992;119:53-61, doi:10.1007/BF01541782.
15. Ostertag CB, Mennel HD, Kiessling M. Stereotactic biopsy of brain tumors. Surg Neurol 1980;14:275-83.
16. Suchorska B, Ruge M, Treuer H, et al. Stereotactic brachytherapy of low-grade cerebral glioma after tumor resection. Neuro Oncol 2011;13:1133-42, doi:10.1093/neuonc/nor100.
17. Popperl G, Kreth FW, Mehrkens JH, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 2007;34:1933-42, doi:10.1007/s00259-007- 0534-y.
18. Shrieve DC, Alexander E 3rd, Wen PY, et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 1995;36:275-82; discussion 282-4, doi:10.1227/00006123- 199502000-00006.
19. Warnke PC, Hans FJ, Ostertag CB. Impact of stereotactic interstitial radiation on brain capillary physiology. Acta Neurochir Suppl (Wien) 1993;58:85-8.
20. Ostertag CB, Weigel K, Warnke P, et al. Sequential morphological changes in the dog brain after interstitial iodine-125 irradiation. Neurosurgery 1983;13:523-8, doi:10.1227/00006123-198311000-00007.
21. Groothuis DR, Wright DC, Ostertag CB. The effect of 125I interstitial radiotherapy on blood-brain barrier function in normal canine brain. J Neurosurg 1987;67:895-902, doi:10.3171/jns.1987.67.6.0895.
22. Julow J, Szeifert GT, Balint K, et al. Tissue response to iodine-125 interstitial brachytherapy of cerebral gliomas. Prog Neurol Surg 2007;20:312-23, doi:10.1159/000100175.
23. Grosu AL, Weber WA, Riedel E, et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:64-74, doi:10.1016/j.ijrobp. 2005.01.045.
24. Grosu AL, Astner ST, Riedel E, et al. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys 2011;81: 1049-58, doi:10.1016/j.ijrobp.2010.07.002.
25. Weber DC, Zilli T, Buchegger F, et al. [(18)F]Fluoroethyltyrosinepositron emission tomography-guided radiotherapy for high-grade glioma. Radiat Oncol 2008;3:44, doi:10.1186/1748-717X-3-44.
26. Niyazi M, Geisler J, Siefert A, et al. FET-PET for malignant glioma treatment planning. Radiother Oncol 2011;99:44-8, doi:10.1016/j.radonc.2011.03. 001.
27. la Fougere C, Suchorska B, Bartenstein P, et al. Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol 2011;13:806-19, doi:10.1093/neuonc/nor054.
28. McDermott MW, Sneed PK, Gutin PH. Interstitial brachytherapy for malignant brain tumors. Semin Surg Oncol 1998;14:79-87, doi:10.1002/(SICI)1098- 2388(199801/02)14:1,79::AID-SSU10.3.0.CO;2-4.
29. Spaeth N, Wyss MT, Weber B, et al. Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence. J Nucl Med 2004;45:1931-8.
30. Brock CS, Young H, O'Reilly SM, et al. Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer 2000;82:608-15, doi:10.1054/bjoc.1999.0971.
31. Yamamoto T, Nishizawa S, Maruyama I, et al. Acute effects of stereotactic radiosurgery on the kinetics of glucose metabolism in metastatic brain tumors: FDG PET study. Ann Nucl Med 2001;15: 103-9, doi:10.1007/BF02988599.
32. Kanai Y, Endou H. Heterodimeric amino acid transporters: molecular biology and pathological and pharmacological relevance. Curr Drug Metab 2001;2:339-54, doi:10.2174/1389200013338324.
33. Langen KJ, Hamacher K, Weckesser M, et al. O-(2-[18F]fluoroethyl)-L- tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 2006;33:287-94, doi:10.1016/j.nucmedbio.2006.01.002.
34. Floeth FW, Pauleit D, Sabel M, et al. 18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med 2006;47:776-82.
35. Salber D, Stoffels G, Pauleit D, et al. Differential uptake of [18F]FET and [3H]l-methionine in focal cortical ischemia. Nucl Med Biol 2006;33:1029-35, doi:10.1016/j.nucmedbio.2006.09.004.
36. Salber D, Stoffels G, Pauleit D, et al. Differential uptake of O-(2-18F-fluoroethyl)-L-tyrosine, L-3H-methionine, and 3H-deoxyglucose in brain abscesses. J Nucl Med 2007;48:2056-62, doi:10.2967/jnumed.107.046615.
37. Pichler R, Dunzinger A, Wurm G, et al. Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance? Eur J Nucl Med Mol Imaging 2010;37:1521-8, doi:10.1007/s00259-010-1457-6.
38. Forsyth PA, Kelly PJ, Cascino TL, et al. Radiation necrosis or glioma recurrence: is computer-assisted stereotactic biopsy useful? J Neurosurg 1995;82:36-44.